Kinetics of triglyceride rich lipoproteins: Chylomicrons and very low density lipoproteins

Atherosclerosis

Volumn 141, Issue SUPPL. 1, 1998, Pages

  Hugh, P ^a   Barrett, R ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b University of Washington   (United States)

Author keywords

In vivo studies; Lipoprotein kinetics; Metabolism

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; CHYLOMICRON; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; RETINOL PALMITATE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CONFERENCE PAPER; LIPOPROTEIN METABOLISM; POSTPRANDIAL STATE; PRIORITY JOURNAL;

EID: 0031774398     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0021-9150(98)00215-9     Document Type: Conference Paper

References (33)

1. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. New Engl J Med 1995;332:512-21.
2. Hokanson J, Austin MA. Plasma triglyceride level is an independent risk factor for cardiovascular disease: a meta-analysis of population based prospective studies. J Cardiovasc Risk 1996;3:213-9.
3. Cohn JS. Postprandial lipid metabolism. Curr Opin Lipidol 1994;5:185-90.
4. Smith D, Proctor SD, Mamo JC. A highly sensitive assay for quantitation of apolipoprotein B-48 using an antibody to human apolipoprotein B and enhanced chemiluminescence. Ann Clin Biochem 1997;34:185-9.
5. Zilversmit DB, Shea TM. Quantitation of apo B-48 and apo B-100 by gel scanning or radio-iodination. J Lipid Res 1989;30:1639-46.
6. Kotite L, Bergeron N, Havel RJ. Quantification of apolipoproteins B-100, B-48, and E in human triglyceride-rich lipoproteins. J Lipid Res 1995;36:890-900.
7. Barrett PHR. Stable isotopes and lipoprotein kinetics; Endogenous labeling and complex systems. Endo Metab 1996;3:71-2.
8. Lichtenstein AH, Hachey DL, Millar JS, Jenner JL, Booth L, Ordovas J, et al. Measurement of human apolipoprotein B-48 and B-100 kinetics in triglyceride-rich lipoproteins using [5,5,5-2H3]leucine. J Lipid Res 1992;33:907-14.
9. Hazzard WR, Bierman EL. Delayed clearance of chylomicron remnants following vitamin-A-containing oral fat loads in broad-β-disease (type III hyperlipoproteinemia). Metabolism 1976;25:777-801.
10. Krasinski SD, Cohn JS, Russell RM, Schaeffer EJ. Postprandial plasma vitamin A metabolism in humans: a reasessment of the use of plasma retinyl esters as markers for intestinally derived chylomicrons and their remnants. Metabolism 1990;39:357-65.
11. Cohn JS, Johnson EJ, Millar JS, Cohn SD, Milne RW, Marcel YL, et al. Contribution of apo B-48 and apo B-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res 1993;34:2033-40.
12. Cortner JA, Coates PM, Le NA, Cryer DR, Ragni MC, Faulkner A, et al. Kinetics of chylomicron remnant clearance in normal and in hyperlipoproteinemic subjects. J Lipid Res 1987;28:195-206.
13. Redgrave TG, Martins LT, Mortimer B-C. Measurement of expired carbon dioxide to assess the metabolism of remnant lipoproteins. J Lipid Res 1995;36:2670-5.
14. 2 breath test to assess the metabolism of triglyceriderich lipoprotein remnants in mice. J Lipid Res 1998;39:691-8.
15. Barrett PHR, Foster DM. Design and analysis of lipid tracer kinetic studies. Curr Opin Lipidol 1996;7:143-8.
16. Gaw A, Packard CJ, Shepherd J. VLDL and LDL turnover: methods and clinical application. Curr Opin Lipidol 1992;3:384-8.
17. Cohn JS, Wagner DA, Cohn SD, Millar JS, Schaefer EJ. Measurement of very low density and low density lipoprotein apolipoprotein (apo) B-100 and high density lipoprotein apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J Clin Invest 1990;85:804-11.
18. Beltz WF, Kesaniemi YA, Miller NH, Fisher WR, Grundy SM, Zech LA. Studies on the metabolism of apolipoprotein B in hypertriglyceridemic subjects using simultaneous administration of tritiated leucine and radioiodinated very low density lipoprotein. J Lipid Res 1990;31:361-74.
19. Parhofer KG, Barrett PHR, Bier DM, Schonfeld G. Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes. J Lipid Res 1991;32:1311-23.
20. Demant T, Packard CJ, Demmelmair H, Stewart P, Bedynek A, Bedford D, et al. Sensitive methods to study human apolipoprotein B metabolism using stable isotope-labeled amino acids. Am J Physiol 1996;270:E1022-36.
21. Felts JM, Itakura H, Crane RT. The mechanism of assimilation of constituents of chylomicrons, very low density lipoproteins and remnants - a new theory. Biochem Biophys Res Commun 1975;66:1467-75.
22. Zambon A, Schmidt I, Beisiegel U, Brunzell JD. Dimeric lipoprotein lipase is bound to triglyceride-rich plasma lipoproteins. J Lipid Res 1996;37:2394-404.
23. Huff MW, Miller DB, Wolfe BM, Connelly PW, Sawyez CG. Uptake of hypertriglyceridemic very low density lipoproteins and their remnants by HepG2 cells: the role of lipoprotein lipase, hepatic triglyceride lipase, and cell surface proteoglycans. J Lipid Res 1997;38:1318-33.
24. Brunzell JD, Hazzard WR, Porte D Jr., Bierman EL. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest 1973;52:1578-85.
25. Karpe F, Steiner G, Olivecrona T, Carlson LA, Hamsten A. Metabolism of triglyceriderich lipoproteins during alimentary lipemia. J Clin Invest 1993;91:748-58.
26. Bjorkegren J, Packard CJ, Hamsten A, Bedford D, Caslake M, Foster L, et al. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J Lipid Res 1996;37:76-86.
27. Packard CJ. Effects of drugs on postprandial lipoprotein metabolism. Proc Nutr Soc 1997;56:745-51.
28. Huff MW, Burnett JR. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Curr Opin Lipidol 1997;8:138-45.
29. Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PHR, Newton RS, et al. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Arterioscler. Thromb Vasc Biol 1997;17:2589-600.
30. Weintraub MS, Eisenberg S, Breslow JL. Lovastatin reduces postprandial lipoprotein levels in hypercholesterolemic patients with mild hypertriglyceridemia. Eur J Clin Invest 1989;19:480-5.
31. Castro Cabezas M, de Bruin TWA, Kock LAW, Kortlandt W, Trip M, Jansen H, et al. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. Metabolism 1993;42:497-503.
32. Gylling H, Relas H, Miettinen TA. Postprandial vitamin A and squalene clearances and cholesterol synthesis off and on lovastatin treatment in type III hyperlipoproteinemia. Atherosclerosis 1995;115:17-26.
33. Pau E, He Y, Lougheed M, Steinbrecher UP. Inhibition of hydroxymethylglutaryl coenzyme A reductase activity does not affect the secretion rate of apolipoproteins B and AI by CaCo-2 cells. Biochem Cell Biol 1995;73:81-90.